BTR is an Australian company based at the Centre for Biospectroscopy at Monash University’s Clayton campus in Victoria. BTR has purchased the exclusive license from Monash University to commercialise the portfolio of diagnostic assets developed by the MCfB.
Specifically, BTR is commercialising the diagnostic platform that delivers a spectroscopy-based method and system for detection of disease agents in blood. This diagnostic platform provides a Point of Care multiplex assay that is rapid, more accurate and cost effective than current diagnostic tests.
After the completion of Australian clinical trials and regulatory approval, BTR will launch the diagnostic platform in the Australian market in early 2019. BTR is pursuing international trials and regulatory approval in specific regional markets.